The CHAMPION-2 study evaluated 3 dose levels of carfilzomib when provided with fixed dose oral cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma. Carfilzomib with cyclophosphamide and dexamethasone is effective and has manageable toxicity. Introduction: This phase 1b study evaluated the safety and efficacy of 3 dose levels of carfilzomib when provided with fixed dose oral cyclophosphamide and dexamethasone (KCyd) in patients with newly diagnosed multiple myeloma (MM). Patients and Methods: CHAMPION-2 was a multicenter single-arm study. Patients with newly diagnosed secretory MM were enrolled and received KCyd treatment for up to 8 cycles. A 3 þ 3 dose escalation scheme was used to evaluate twice-weekly carfilzomib at 36, 45, and 56 mg/m 2 dose levels, followed by a dose expansion. Results: No dose-limiting toxicities were observed in any of the dose evaluation cohorts. The KCyd regimen that included the maximum planned carfilzomib dose of 56 mg/m 2 twice weekly was brought forward into dose expansion. A total of 16 patients were treated at this dose level. At 56 mg/m 2 the overall response rate was 87.5% (95% confidence interval, 61.7-98.4), and the median time to response of 14 patients whose disease responded to therapy was 1 month. At this dose level, common adverse events of grade 3 or higher were anemia (25.0%), neutropenia (18.8%), acute kidney injury (12.5%), and decreased white blood cell count (12.5%). Ten of 16 patients who received carfilzomib at 56 mg/m 2 completed all 8 cycles, 5 patients discontinued study therapy before cycle 8 as a result of adverse events, and 1 patient discontinued therapy as a result of progressive disease. Conclusion: Carfilzomib in combination with cyclophosphamide and dexamethasone is effective and has manageable toxicity for patients with newly diagnosed MM.
Introduction
Carfilzomib is a selective second-generation proteasome inhibitor. 1, 2 In a randomized phase 3 head-to-head trial (ENDEAVOR) comparing proteasome inhibitors in combination with low-dose dexamethasone, carfilzomib at 56 mg/m 2 twice weekly resulted in significantly improved progression-free survival over bortezomib in relapsed or refractory multiple myeloma (MM) (18.7 months vs. 9.4 months; hazard ratio, 0.53; P < .0001). 3 Overall survival in ENDEAVOR was also significantly improved for the carfilzomib group compared to the bortezomib group (47.6 months vs. 40.0 months; hazard ratio, 0.79; P ¼ .0100).
Alkylating agents have been used to treat MM since the 1960s. Since the introduction of proteasome inhibitor therapy 15 years ago, triplet combinations that include an alkylator, a proteasome inhibitor, and a steroid have moved into frontline myeloma therapy. 5 Several studies have demonstrated the activity of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) combinations in previously untreated MM, with rates of very good partial response (VGPR) or better ranging from 37% to 61%. [6] [7] [8] CyBorD is a preferred regimen recommended by the National Comprehensive Cancer Network (NCCN) MM panel for the frontline treatment of MM in both transplant-eligible and transplant-ineligible patients. 5 Despite the success of CyBorD, few trials have been performed to study the combination of the proteasome inhibitor carfilzomib with cyclophosphamide and dexamethasone (KCyd) for MM patients. In a prior study by Bringhen et al, 9 58 transplant-ineligible, newly diagnosed MM patients were enrolled and treated with up to 9 cycles of KCyd (36 mg/m 2 ) followed by maintenance therapy.
The objectives of this phase 1b study were to evaluate the safety and tolerability of twice-weekly carfilzomib when used in combination with cyclophosphamide and dexamethasone for the treatment of newly diagnosed MM patients, and to estimate the overall response rate (ORR) and time to response (TTR). Whereas the population in Bringhen et al 9 was limited to transplant-ineligible patients who were ! 65 years of age, patients in this study were ! 18 years of age and were enrolled regardless of transplant eligibility.
Methods
This was a phase 1b, multicenter, open-label, dose-escalation study of twice-weekly carfilzomib provided in combination with oral cyclophosphamide and dexamethasone to patients with newly diagnosed MM (ClinicalTrials.gov identifier NCT01980589). Patients 18 years or older with newly diagnosed symptomatic MM and measurable disease were eligible. Inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; left ventricular ejection fraction ! 40%; adequate hepatic function (bilirubin < 1.5 times the upper limit of normal, and aspartate aminotransferase and alanine aminotransferase < 3 times the upper limit of normal); absolute neutrophil count ! 1.0 Â 10 9 /L; platelet count ! 50 Â 10 9 /L; and creatinine clearance ! 15 mL/min. Patients were excluded if they had MM of immunoglobulin M subtype, plasma-cell leukemia, Waldenstrom macroglobulinemia, grade 2 or higher neuropathy, active congestive heart failure (New York Heart Association Class III or IV), symptomatic ischemia, or myocardial infarction within 6 months before enrollment. This study permitted stem-cell collection but did not permit autologous hematopoietic stem-cell transplantation while the patient was on the study protocol. Written consent was obtained from all patients, and the study protocol received institutional review board approval by all participating institutions.
The trial was originally designed as a phase 1b/2 trial, with treatment to include 8 cycles of induction therapy with KCyd, followed by randomization to maintenance carfilzomib therapy versus observation. In 2014, as a result of slow enrollment and competing trials, the protocol was amended to include only the phase 1b component and only induction. Treatment was therefore provided with KCyd in 28-day cycles and was continued for 8 cycles, or until progression of disease, unacceptable toxicity, withdrawal of consent, or death. , and 56 mg/m 2 dose levels followed by a dose-expansion cohort. The maximum tolerated dose (MTD) of KCyd was defined as the highest carfilzomib dose at which < 33% of patients had a treatment-related dose-limiting toxicity during the first 28-day treatment cycle. Dose-limiting toxicities were defined as any of the following treatment-related adverse events: grade 3 or higher nonhematologic toxicity; grade 3 or higher acute kidney injury lasting > 72 hours; grade 4 neutropenia lasting for > 7 days; febrile neutropenia of any duration; grade 4 thrombocytopenia that persisted for > 14 days despite holding treatment; or grade 3 or 4 thrombocytopenia associated with > grade 1 bleeding.
The primary end point of this study was the MTD of carfilzomib provided twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed MM, and secondary end points were ORR, TTR, and safety. Overall response was defined as a best response of stringent complete response, complete response (CR), VGPR, or partial response using the International Myeloma Working Group Uniform Response Criteria per investigator assessment. Under the amended protocol (induction KCyd therapy only), patients were followed for 30 days after last treatment, and progression-free survival was not evaluated.
Determination of adverse event severity was based on the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). This study was supported by Onyx Pharmaceuticals Inc, an Amgen Inc subsidiary.
Results
Twenty-two patients were enrolled onto this study, which was conducted at 9 US centers between August 29, 2013, and confidence interval, 61.7-98.4) ( Table 3 ). The best overall responses in the 56 mg/m 2 cohort were CR (n ¼ 1), VGPR (n ¼ 7), and partial response (n ¼ 6) ( Table 3 ). The median TTR for the 14 patients whose disease responded to therapy in the 56 mg/m 2 dose cohort was 1 month (range, 0.9-2.8 months; Table 3 ). Disease of 2 patients in the 36 mg/m 2 dose cohort responded; the TTR was 1.0 month and 1.6 months, respectively. All patients in the 45 mg/m 2 dose cohort responded with a median TTR of 0.8 months (range, 0.7-1.9 months; Table 3 ). Patients were followed for 30 days beyond last treatment (a median follow-up of 7.2 months), and thus progression-free survival was not assessed.
Discussion
Cyclophosphamide and dexamethasone have been combined with bortezomib (CyBorD, VCD, and VCD-mod) for the treatment of newly diagnosed MM in several prior studies, [6] [7] [8] 10 and current NCCN guidelines list CyBorD as a preferred regimen for both newly diagnosed and relapsed MM treatment. 5 Though different groups used somewhat different dosing schedules to evaluate CyBorD, all showed encouraging response rates with responses of VGPR or greater ranging from 37% to 61%. [6] [7] [8] 10 Response rates to cyclophosphamide, bortezomib, and dexamethasone triplet regimens are thus similar to the 50% VGPR or better seen here and the 71% rate of VGPR or better seen for KCyd with 36 mg/m 2 twiceweekly carfilzomib dosing by Bringhen et al. 9 Other studies of carfilzomib in newly diagnosed MM have reported rates of VGPR or better of 72% for carfilzomib, lenalidomide, and low-dose dexamethasone (carfilzomib at 36 mg/m 2 , n ¼ 36 patients) and of 58% for carfilzomib, melphalan, and prednisone (carfilzomib at 36 mg/m 2 , n ¼ 50 patients).
11,12
The rate of peripheral neuropathy observed in trials of CyBorD is higher than that reported among patients treated with KCyd. For example, Reeder et al 8 reported that any-grade peripheral neuropathy occurred in 66% of patients who received CyBorD (with twice-weekly bortezomib), whereas we found that any-grade 
Conclusion
Combination regimens for carfilzomib continue to be explored to optimize efficacy and safety. The findings reported here for the phase 1b CHAMPION-2 study demonstrate that carfilzomib administered twice weekly can be used at 56 mg/m 2 in combination with cyclophosphamide and dexamethasone for newly diagnosed MM. The results reported here are consistent with another phase 2 study of KCyd in transplant-ineligible, newly diagnosed MM that included 36 mg/m 2 carfilzomib. 9 KCyd represents a novel option for newly diagnosed MM that is effective and has manageable toxicity.
Clinical Practice Points
Carfilzomib is a selective, irreversible proteasome inhibitor currently approved for the treatment of relapsed and refractory MM. The CHAMPION-2 study evaluated 3 dose levels of carfilzomib when provided as a component of KCyd combination therapy in patients with newly diagnosed MM. 
